Recherche - Université de Picardie Jules Verne Accéder directement au contenu

Filtrer vos résultats

11 Résultats
authFullName_s : Jean-Pierre Bronowicki

ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Isabelle Ollivier-Hourmand , Yohann Repesse , Pierre Nahon , Cendrine Chaffaut , Thông Dao , et al.
Liver International, 2022, 42 (6), pp.1386-1400. ⟨10.1111/liv.15159⟩
Article dans une revue hal-03553907v1

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Christophe Hezode , Dominique Guyader , Eric Nguyen-Khac , Dominique Larrey , Regine Truchi , et al.
Hepatology, 2018, 68 (1), pp.374A
Article dans une revue hal-03590862v1
Image document

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Manon Allaire , Pierre Nahon , Richard Layese , Valérie Bourcier , Carole Cagnot , et al.
Hepatology, 2018, 68 (4), pp.1245-1259. ⟨10.1002/hep.30034⟩
Article dans une revue hal-02648452v1

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

Pierre Nahon , Jessica Bamba-Funck , Richard Layese , Eric Trépo , Jessica Zucman-Rossi , et al.
Journal of Hepatology, 2022, ⟨10.1016/j.jhep.2022.11.003⟩
Article dans une revue hal-03883705v1

Changes in serum bile acid levels associated with bezafibrate add-on therapy in patients with primary biliary cholangitis and inadequate biochemical response to ursodeoxycholic acid: results from the BEZURSO trial (NCT01654731)

Christophe Corpechot , Olivier Chazouilleres , Lydie Humbert , Alexandra Rousseau , Antonia Le Gruyer , et al.
Hepatology, 2017, 66 (1, SI), pp.168A
Article dans une revue hal-03590928v1

Sofosbuvir plus velpatasvir plus voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program

Christophe Hezode , Dominique Guyader , Eric Nguyen-Khac , Dominique Larrey , Regine Truchi , et al.
Journal of Hepatology, 2019, 70 (1, 1), pp.E224. ⟨10.1016/S0618-8278(19)30417-7⟩
Article dans une revue hal-03590860v1
Image document

Large-scale screening of lipase acid deficiency in at risk population

Abdellah Tebani , Bénédicte Sudrié-Arnaud , Hela Boudabous , Anais Brassier , Rodolphe Anty , et al.
Clinica Chimica Acta, 2021, 519, pp.64-69. ⟨10.1016/j.cca.2021.04.005⟩
Article dans une revue hal-03223991v1

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study

Tarik Asselah , Stanislas Pol , Christophe Hezode , Veronique Loustaud-Ratti , Vincent Leroy , et al.
Liver International, 2020, 40 (5), pp.1042-1051. ⟨10.1111/liv.14313⟩
Article dans une revue hal-03590858v1

Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort

Eric Nguyen-Khac , Pierre Nahon , Olivier Ganry , Hajer Ben Khadhra , Philippe Merle , et al.
European Journal of Gastroenterology & Hepatology, 2023, ⟨10.1097/MEG.0000000000002546⟩
Article dans une revue hal-04182844v1

Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program

Christophe Hézode , Victor De Ledinghen , Hélène Fontaine , Fabien Zoulim , Pascal Lebray , et al.
Hepatology, 2015, 62, pp.314A--314A. ⟨10.1002/hep.28160⟩
Article dans une revue hal-01380169v1

Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection

Tarik Asselah , Stanislas Pol , Christophe Hezode , Veronique Loustaud Ratti , Vincent Leroy , et al.
Hepatology, 2018, 68 (1), pp.385A
Article dans une revue hal-03590861v1